Product for increasing patient compliance
Patent Information
- Application Number
- HK32026120937
- Authority / Receiving Office
- HK · HK
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2025-09-17
- Filing Date
- 2026-03-23
- Publication Date
- 2026-09-04
- Estimated Expiration
- 2034-03-22
Abstract
Description
Product Technical Field for Improving Patient Compliance
[0001] This utility model generally relates to ensuring patients adhere to their prescribed drug treatment regimens. Background Art
[0002] The following discussion of the background art of this utility model is only for the purpose of helping to understand this utility model. It should be understood that this discussion is not an admission or endorsement of any content mentioned in this application that is common knowledge or has been disclosed or known to those skilled in the art in any jurisdiction prior to the priority of this utility model.
[0003] When an oral pharmaceutical composition uses a diaminophenazine (DAPTZ) compound as the active ingredient (e.g., using colorless methylene blue (LMT) compound alone, or a combination of colorless methylene blue (LMT) and methylene oxide (MT+) compound), the formulation gradually exhibits an irregular blue discoloration as the colorless methylene blue (LMT) oxidizes. As shown in Figure 1, this discoloration gives the tablet a mold-like appearance. Although the uneven mottled appearance of the formulation surface may affect the appearance, it still maintains the effectiveness of the active ingredient and can treat Alzheimer's disease. Patients often hesitate to take tablets with this appearance due to concerns about drug deterioration, and caregivers are also often reluctant to administer medication to patients as a result, which significantly affects medication adherence.
[0004] Furthermore, in some regions, counterfeit drugs may pose a serious problem. In particular, when the surface of oral medication tablets has an uneven, mottled appearance, it is more likely to raise questions about their authenticity from patients and / or caregivers. Due to the low risk of crime and the large profit margin, drug counterfeiting has always been a pressing problem to be solved.
[0005] According to a review report by the World Health Organization (WHO), approximately 10% to 30% of medicines in low- and middle-income countries are substandard or counterfeit. This additional concern about potentially counterfeit drugs further exacerbates the situation where patients and / or caregivers are hesitant to take or administer tablets with an uneven appearance due to concerns about drug authenticity, thus often affecting medication adherence.
[0006] Currently, there are various solutions to reduce the risk of drug counterfeiting, including using serialization technology to ensure supply chain security and using unique drug designs or shapes. While unique drug designs or shapes can make them easier for patients, caregivers, and pharmacists to identify, these distinctive appearance features, like serial numbers, can also be easily copied by counterfeiters.
[0007] There is an urgent need for a technical solution that can improve patient medication adherence and at least solve any of the above-mentioned problems. Summary of the Invention
[0008] This invention provides a film coating that encapsulates a formulation containing a diaminophenazine (DAPTZ) compound as the active ingredient, thereby masking the uneven and mottled appearance of the formulation and improving patient adherence.
[0009] Therefore, one aspect of the present invention relates to an oral pharmaceutical composition comprising: (a) a formulation comprising: (i) a diaminophenazine compound (DAPTZ) as an active ingredient, said diaminophenazine compound being selected from methylene blue (MT+) compounds, colorless methylene blue (LMT) compounds, or combinations thereof; (ii) one or more other accompanying active ingredients, additives, excipients, diluents, binders, lubricants, disintegrants, fillers, stabilizers, surfactants, antioxidants, or combinations thereof; (b) a film coating covering said formulation comprising: a film-forming polymer, a water-soluble plasticizer, a film-forming auxiliary polymer, and blue pigment particles; (c) silica microparticles embedded within said film coating and / or attached to said film coating surface.
[0010] Other aspects and features of the present invention will become apparent to those skilled in the art from the description of specific embodiments of the present invention taken in conjunction with the accompanying drawings.
[0011] Brief Description of the Drawings To more clearly illustrate the technical solutions in the embodiments of the present utility model or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the elements or parts are not necessarily drawn to actual scale. Obviously, the drawings described below are some embodiments of the present utility model. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0012] In the drawings, embodiments of the present utility model are shown only by way of non-limiting example. [Figure 1]: Schematally shows an oral pharmaceutical composition with diaminophenazine (DAPTZ) compound as the active ingredient. Over time, the color of the colorless methylene blue (LMT) compound oxidizes, and its color changes to blue in a disordered pattern.
[0013] [Figure 2]: Schematively showing the appearance of an oral pharmaceutical composition with a diaminophenazine (DAPTZ) compound as the active ingredient over time, when the formulation is encapsulated in the following film coatings: (A) no pigment, (B) orange-yellow pigment, or (C) blue (Indigo) pigment.
[0014] [Figure 3]: Schematably showing the presence of at least two or more silica particles with different pore sizes in each particle.
[0015] [Figure 4]: Schematably showing the appearance of an oral pharmaceutical composition with a diaminophenazine (DAPTZ) compound as the active ingredient over time, when the formulation is encapsulated in a film coating containing Indigo blue pigment and embedded with silica particles.
[0016] [Figure 5]: Preferred shapes of oral pharmaceutical compositions with diaminophenazine (DAPTZ) compounds as active ingredients: (A) hexagon, (B) octagon, (C) pentagon, (D) heptagon, (E) nonagon, (F) decagon, (G) dodecagon.
[0017] [Figure 61: Schematically showing the reflectance spectral pattern observed by a spectrometer, wherein the diaminophenazine (DAPTZ) formulation is encapsulated in a film coating containing indium blue pigment, and silica microparticles are embedded in the film coating, and two sets of silica microparticles are embedded in the film coating in a patterned manner. 2 HK 30137243 A Specification Detailed Description
[0018] In this document, unless otherwise stated to the contrary, the terms “comprising,” “consisting of,” “having,” etc., shall be interpreted in a non-exhaustive manner, that is, meaning “including but not limited to.”
[0019] Furthermore, throughout this document, unless the context otherwise requires, the word “comprising” or variations thereof such as “including” or “covering” should be understood to mean the inclusion of the said integer or group of integers, but not to exclude any other integer or group of integers.
[0020] Unless otherwise defined, all other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which they pertain.
[0021] According to various embodiments, the present invention relates to an oral pharmaceutical composition comprising: (a) a formulation comprising: (i) a diaminophenazine compound (DAPTZ) as an active ingredient, said diaminophenazine compound being selected from methylene blue (MT+) compounds, colorless methylene blue (LMT) compounds, or combinations thereof; (ii) one or more other accompanying active ingredients, additives, excipients, diluents, binders, lubricants, disintegrants, fillers, stabilizers, surfactants, antioxidants, or combinations thereof; (b) a film coating covering said formulation comprising: a film-forming polymer, a water-soluble plasticizer, a film-forming auxiliary polymer, and blue pigment particles; (c) silica microparticles embedded within said film coating and / or attached to said film coating surface.
[0022] Initially, the gelatin capsule shell crosslinks with MT groups, thereby interfering with the dissolution of MT in the stomach and its oral absorption from the gastrointestinal tract. This led to increased gastrointestinal side effects observed in clinical trials in pigs, which were more pronounced compared to formulations not encapsulated in angiotensin. The amount of methylene blue (MT) compound in the formulation would be a therapeutically effective dose. However, experimental observations showed that very high doses (delayed dissolution) resulted in limited nominal dose absorption in the stomach via the reductase mechanism, leading to undesirable delayed absorption in the small intestine via dimer formation at higher pH values.Therefore, in various embodiments, the dosage unit of the methylene blue (MT) compound is less than 120 mg. In various embodiments, the dosage unit of the methylene blue (MT) compound is less than 100 mg. In various embodiments, the dosage unit of the methylene blue (MT) compound is less than 70 mg, preferably 40-70 mg (e.g., 40, 45, 50, 55, 60, 65, or 70 mg), and is administered 3 or 4 times daily. In various embodiments, for gastric retention formulations, the dosage unit of the methylene blue (MT) compound can be increased to at least 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg, or even more, including 200, 300, 400, and 500 mg, without causing side effects.
[0023] In various embodiments, the colorless methylene blue (LMT) compound comprises a crystalline form. This may be unavoidable if the stabilized crystalline reduced diaminophenazine (DAPTZ) compound composition of the present invention contains at least some of the corresponding oxidized compounds as impurities. In various embodiments, the amount of colorless methylene blue (LMT) compound in the star form is a therapeutically effective amount. In various embodiments, the dosage of the reduced DAPTZ compound colorless methylene blue (LMT) as described in the 3 HK 30137243 A specification is between 1 and 1000 mg. Therefore, in various embodiments, once-daily or more star units can reach 1000 mg or more (e.g., 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mg) and can be considered effective. In various embodiments, the formulation of the colorless methylene blue (LMT) compound is from 4 mg twice daily to 8 mg twice daily. In various embodiments, the formulation of the colorless methylene blue (LMT) compound is most commonly 8 mg twice daily. In various embodiments, the formulation of the colorless methylene blue (LMT) compound is 60-100 mg three times daily. In various embodiments, this is a sustained-release or delayed-release formulation, with the release amount less than 50% within 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or 8 hours.
[0024] Suitable additives, excipients, diluents, binders, lubricants, disintegrants, fillers, stabilizers, surfactants, antioxidants, or combinations thereof can be found in standard pharmaceutical literature.For example, see the Handbook of Pharmaceutical Additives, 2nd edition (edited by M. Ash and I. Ash), 2001 (Synapse Information Resources, Inc., Endicott, NY, USA), Remington Pharmaceutical Sciences, 20th edition, 2000 (Lippincott, Williams & Wilkins), and the Handbook of Pharmaceutical Excipients, 2nd edition, 1994. In all embodiments, each additive, excipient, diluent, binder, lubricant, disintegrant, filler, stabilizer, surfactant, antioxidant, or combination thereof should be pharmaceutically acceptable. The term “pharmaceuticalally acceptable,” as used herein, refers to compounds, ingredients, materials, compositions, dosage forms, etc., that, within reasonable medical judgment, are suitable for use in the tissues of a subject (e.g., a human) without causing excessive toxicity, irritation, allergic reactions, or other problems or complications, consistent with a reasonable benefit / risk ratio. In various embodiments, each additive, excipient, diluent, binder, lubricant, disintegrant, filler, stabilizer, surfactant, antioxidant, or combination thereof must also be "acceptable," i.e., compatible with other components in the formulation. In various embodiments, the additive is a nonionic surfactant. In various embodiments, the surfactant is a nonionic surfactant. In various embodiments, the additive is an emulsifier. In various embodiments, the additive is lauroyl polyoxyethylene-32 glycerol. In various embodiments, the additive is hydrophilic fumed silica with a specific surface area of 200 m² / g.
[0025] In various embodiments, the film coating comprises a powder composition comprising a film-forming polymer, such as phthalic acid-vinyl acetate phthalate (phthalic acid-PVAP) or partially hydrolyzed polyvinyl alcohol (PVA), a water-soluble plasticizer, an auxiliary film-forming polymer (such as sodium alginate or methylcellulose), pigment particles, and optionally an anti-caking agent. The coating suspension is prepared by mixing this powder with water and adding an anti-agglomeration agent to prevent the coating suspension from clogging the nozzles and pipes of the spray gun device.
[0026] In various embodiments, when the film-forming polymer of the film coating includes titanium-PVAP, the PVAP preferably contains about 55-62% phthalate and 10% titanium dioxide mixed in during the PVAP manufacturing process. When large halo pigment particles are used with PVAP, the polymerization reaction of PVAP will be interfered with. However, by adding 10% titanium dioxide to the PVAP for titanium-based treatment, at least 15% (by weight) of the film coating powder can be pigment particles.In various embodiments, when the film-forming polymer of the film coating includes phthalic acid-PVAP, the particle size of the phthalic acid-PVAP is less than 100 micrometers. In various embodiments, the particle size of the phthalic acid-PVAP is less than 25 micrometers. In various embodiments, the phthalic acid-PVAP accounts for about 70-85% of the weight of the film-coated dry powder. In various embodiments, the phthalic acid-PVAP accounts for 75-80% of the weight of the film-coated dry powder. In various embodiments, the phthalic acid-PVAP accounts for about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, or about 85% of the weight of the film-coated dry powder.
[0027] In various embodiments, the water-soluble plasticizer includes polyethylene glycol. In various embodiments, the water-soluble plasticizer includes polyethylene glycol 3350. In various embodiments, the water-soluble plasticizer comprises polyethylene glycol 8000. In various embodiments, the water-soluble plasticizer comprises polyethylene oxide. In various embodiments, the water-soluble plasticizer comprises polyethylene oxide. In various embodiments, the water-soluble plasticizer accounts for 10-20% of the weight of the film-coated dry powder. In various embodiments, the water-soluble plasticizer accounts for about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% of the weight of the film-coated dry powder.
[0028] In various embodiments, the auxiliary film-forming polymer is present in the dry powder, which has the advantage of assisting in the formation of a film on the tablet and, as a suspending agent for polymer particles in the coating suspension, providing a more uniform coating. In various embodiments, the auxiliary film-forming polymer comprises sodium alginate. In various embodiments, the content of sodium alginate can be up to 3% of the weight of the dry powder. In various embodiments, the sodium alginate content ranges from 1-1.50% of the coating powder. In various embodiments, the sodium alginate is of medium viscosity grade. Sodium alginate has many advantages because it is a food-grade product suitable for human consumption; it is a water-soluble polymer that increases the viscosity of the coating suspension and helps the coating adhere to the tablet surface when the PVAP particles fuse to form a film. This means that sodium alginate thickens the coating suspension, thereby inhibiting particle sedimentation and acting as a suspending agent, while also acting as a film-forming agent. Although sodium alginate is water-soluble, it is insoluble in low-pH environments such as gastric juices (e.g., the acidic environment of the stomach), therefore sodium alginate will not disintegrate in gastric juices and thus will not interfere with enteric coating properties. Sodium alginate acts as a suspending agent for the PVAP particles in the coating suspension. During the spraying process, sodium alginate also acts as a film-forming agent, assisting in providing a uniform coating on the tablet.A uniform coating is more likely to mask the uneven, mottled appearance of oxidized DAPTZ compounds. In various embodiments, the film-forming polymer includes methylcellulose, such as A4C, a methylcellulose produced by Dow Chemical Company. In various embodiments, the amount of methylcellulose used can be up to 1.50% of the dry powder weight. In various embodiments, the range of methylcellulose used is 1-1.50% of the dry powder weight.
[0029] In various embodiments, the pigment particles can be any pigment in the coating dispersion such as pharmaceutical tablets. In various embodiments, the pigment particles can be FD&C lake and D&C lake, titanium dioxide, magnesium carbonate, talc, silica, iron oxide, carbon black, and insoluble dyes. In addition, natural pigments such as riboflavin, lipofuscin 40, curcumin, and paprika are also included. In various embodiments, the pigment particles include blue pigment particles. In various embodiments, the blue pigment particles comprise 1H-hydroxy-5-sulfonic acid, 2-(1,3-dihydro-3-oxo-5-sulfonyl-2H-hydroxy-2-yl)-2,3-dihydro-3-oxo-aluminum complex, also known as FD&C Blue 2 Indium Blue Phenylene Red Aluminum Lake and D&C Blue 2 Indium Blue Phenylene Red Aluminum Lake according to US FDA regulations, or as E132 Indium Blue Phenylene Red Aluminum Lake according to EU regulations, with an absorption range of 600 nm to 610 nm. In various embodiments, the pigment particles comprise disodium 6-hydroxy-5-[(4-sulfobenzoyl)azo]-2-phenylenesulfonic acid, which, according to US FDA regulations, may also be known as FD&C Yellow 6 Orange or E110 as specified in Europe, with an absorption range between 443 nm and 480 nm.
[0030] In various embodiments, the silica microparticles are thin porous silicon films made by processing silicon wafers, with tunable pore density embedded within them. The pore size can be controlled by changing the current density applied during the etching process. In various embodiments, etching is performed by acid etching in the presence of current. The etching process forms tiny pores or cavities in the silicon wafer, the size of which is controlled by the current density of the etching current waveform. The controlled dimensions include the depth of the pores etched in the silicon film, as well as the diameter and density of the pores; the size and density of the pores are adjusted by controlling the current density over time. Although the pore size varies with the current density, they are nanopores, with pore diameters much smaller than the wavelength of optical light. Therefore, when irradiated by incident photons, the optical properties of porous silicon are similar to the average properties of silicon and air in porous silicon at a distance close to the photon wavelength. By adjusting the pore density as a function of film depth, the refractive index of the porous silicon film also varies accordingly between the refractive indices of pure silicon and air.Decreasing the current leads to a smaller pore size, and vice versa. This process controls the optical properties of the silicon film, which also extend to the optical properties of the silica microparticles obtained through oxidation. In various embodiments, the silicon is etched, pulverized, and then oxidized. Specific optical spectra, whether reflectance or transmission, can be described by distinguishable characteristics such as the shape, number, position, or amplitude of peaks. The unique characteristics of a specific spectrum combine to form a unique and identifiable discrete set of distinct characteristic values. In various embodiments, the silica microparticles are amorphous nanoporous silica microparticles, wherein each microparticle contains at least two or more different pore sizes. In various embodiments, the silica microparticles are amorphous nanoporous silica microparticles, wherein each microparticle contains at least three, four, five, six, seven, or more different pore sizes. The optical effects of these different pore sizes make the colors or pigments observed through these silica microparticles appear mixed or uniform, presenting uniform spots rather than uneven mottles.
[0031] In various embodiments, silica microparticles are embedded in a film coating and mixed with the dry powder before the addition of water and the coating formulation. When the silica microparticles are embedded in the film coating, they additionally act as an anti-caking agent, as a processing aid, and to prevent the dry powder from agglomerating. Since the spectral characteristics of the silica microparticles may be affected by chemical interactions within the film coating, it is preferable to control the amount of silica microparticles to 1.00% or less of the powder weight to embed them in the film coating, and preferably to embed the silica microparticles in the film coating after the film coating is sprayed onto the formulation.
[0032] The anti-agglomerating agent or stabilizer may be a 30% aqueous ammonia solution (NH4OH), which can be used up to 8.00 ml per 100 g of solids in the coating suspension, preferably about 4.00 ml per 100 g of solids. Ammonia is not part of the coating powder; it is added after the coating powder has been suspended in water for approximately 30 minutes, prior to the spraying step. The coating suspension can be sprayed without the addition of an anti-agglomerate, but clogging problems may occur if the spraying equipment temperature is too high. If an anti-agglomerate is added to the coating suspension, the coating suspension will not begin to agglomerate and clog the spraying device before the temperature reaches approximately 60°C, whereas without an anti-agglomerate, the coating suspension may begin to agglomerate and clog the spraying device at a temperature of approximately 27-30°C.
[0033] In various embodiments, silica microparticles are embedded in the film coating after the film coating is sprayed onto the formulation. In various embodiments, the silica microparticles are pressed into the film coating sprayed onto the formulation before the film coating dries.In various embodiments, the silica microparticles comprise two sets of amorphous nanoporous silica microparticles. The first set of amorphous nanoporous silica microparticles contains at least two or more different pore sizes per particle and has a first detectable spectral range. The second set of amorphous nanoporous silica microparticles contains at least two or more different pore sizes per particle and has a second detectable spectral range, wherein the first detectable spectral range differs from the second detectable spectral range. This is achieved by varying the current density to form the first detectable spectral range and then varying it within different current density ranges to form the second detectable spectral range. In various embodiments, the silica microparticles are patterned and pressed into the film coating before the film coating is sprayed onto the formulation and dried. This pattern is formed by staggering the arrangement of the first and second sets of silica microparticles. In various embodiments, the first and second sets of amorphous nanoporous silica microparticles are staggered at adjacent positions on the film coating to form a pattern. In various embodiments, a first group of silica microparticles is embedded in a film coating by being incorporated into a dry material, and a second group of silica microparticles is pressed into the film coating in a patterned manner before the film coating is sprayed onto the formulation and dried. In other various embodiments, a first group of silica microparticles is embedded in a film coating by being incorporated into a dry material, and both the first and second groups of silica microparticles are pressed into the film coating in a patterned manner before the film coating is sprayed onto the formulation and dried. This pattern is invisible to the naked eye, difficult to detect, and difficult to replicate. The pattern in the first and second detectable spectral ranges can be detected using a spectrometer. In this way, the spectral range of the silica microparticles has two advantages: (1) providing a uniform appearance, making the oral pharmaceutical composition appear as uniform spots rather than uneven patches; and (2) providing a detectable pattern to reduce counterfeiting. Both of these advantages contribute to improving patient compliance, as the tablets appear safe to take and it can be determined whether they are genuine, safe-to-take medications.
[0034] Referring to [Figure 2], it can be seen that the transparent film coating only slightly reduces the uneven, mottled appearance of oxidized DAPTZ that becomes visible over time. Orange and blue pigment particles can reduce this phenomenon to some extent. The film coating containing blue pigment has the best covering effect.
[0035] [Figure 3] shows that there are at least two or more silica particles with different pore sizes in each particle. Referring to [Figure 4], it can be seen that when observing oxidized DAPTZ coated with blue pigment film through silica particles embedded in the surface, its optical effect presents a mixed or uniform appearance, making it look like uniform spots rather than uneven mottles. The closer the pigment color is to oxidized DAPTZ, the better the optical effect.The absorption range of oxidized DAPTZ is typically between 665 and 670 nm, while the pigments exhibiting the best optical performance have an absorption range of 600 nm to 610 nm.
[0036] It should be noted that the circular shape of the oral pharmaceutical composition is prone to significant rolling when dropped. Many patients who will take this oral pharmaceutical composition are older and may have motor and flexibility impairments, making the circular oral pharmaceutical composition more likely to fall and roll. In various embodiments, the shape of the oral pharmaceutical composition has multiple interior angles of more than 90 degrees. The benefit of adding angles to the oral pharmaceutical composition is to reduce its rolling when dropped. However, adding only four angles may make the oral pharmaceutical composition appear sharp and angular, which may be psychologically perceived as difficult to swallow. In various embodiments, the multiple interior angles include five or more interior angles, six or more interior angles, seven or more interior angles, eight or more interior angles, nine or more interior angles, ten or more interior angles, eleven or more interior angles, or twelve or more interior angles. In various embodiments, when multiple angles are added, it is preferable that the overall shape of the oral pharmaceutical composition still appears circular. In various embodiments, an oral pharmaceutical composition with multiple interior angles may have six 120-degree angles, presenting a hexagonal appearance [Fig. SA]. In various embodiments, an oral pharmaceutical composition with multiple interior angles may have eight 135-degree angles, presenting an octagonal appearance [Fig. SB]. In various embodiments, an oral pharmaceutical composition with multiple interior angles may have five 108-degree angles, presenting a pentagonal appearance [Fig. SC]. In various embodiments, an oral pharmaceutical composition with multiple interior angles may have seven 128.6-degree angles, presenting a heptagonal appearance [Fig. SD]. In various embodiments, an oral pharmaceutical composition with multiple interior angles may have nine 140-degree angles, presenting a nonagonal appearance [Fig. SE]. In various embodiments, an oral pharmaceutical composition with multiple interior angles may have ten 144-degree angles, presenting a decagonal appearance [Fig. SF]. In various embodiments, an oral pharmaceutical composition with multiple interior angles may have 12 angles of 150 degrees, presenting a dodecagonal appearance [Fig. SG]. It should be appreciated that other shapes with multiple angles may also be used, which generally appear almost circular, providing angles that can slow or prevent the oral pharmaceutical composition from rolling, but still maintaining an overall rounded appearance, giving a feeling of easy swallowing.
[0037] When the oral pharmaceutical composition in [Fig. 4] is observed by a spectrometer, an enlarged pattern can be generated by utilizing the spectral differences between the silica particles, similar to the pattern of the embedded film-coated silica particles shown in [Fig. 6].Referring to [FIG. 61, it can be seen that in the magnified spectral image of the generated oral pharmaceutical composition, the first group of particles having a first detectable spectral range is in the shape of a star cross, and the second group of particles in the surrounding area is offset therefrom, having a second detectable spectral range, whereby the pattern of a star cross can be seen. As would be understood by a person skilled in the art, the first group of silica particles embedded in or on the film coating and the second group of silica particles embedded in or on the film coating can be used to form various patterns on the oral pharmaceutical composition.
[0038] Example of DAPTZ preparation A 3,7-diamino-10H-phenothiazine compound, also known as leucomethylene blue (LMT) compound, with the following structural formula, is formulated into a stable crystalline form for use as an active ingredient in the method.
[0039] reduced form The preparation comprises 100 mg of the active ingredient leucomethylene blue (LMT) compound, a nonionic surfactant lauroyl macrogol-32 glycerides, and an additive hydrophilic fumed silica with a specific surface area of 200 m2 / g.
[0040] Color test The following preparations are first prepared as dry powder, then suspended in cold water at about 15°C at a gram-to-milliliter ratio of 3:17, and mixed for 20-30 minutes. An aqueous ammonia solution of 18 mol / L is added, which accounts for about 30% of the volume of water used. Subsequently, the suspension is filtered and sprayed onto the preparation containing DAPTZ compound as the active ingredient.
[0041] [Table 1]: Transparent film coating used in [Figure 2A] 9 HK 30137243 A Specification Film coating composition Film-forming polymer Iron-based PVAP Water-soluble plasticizer PEG 3500 Auxiliary film-forming polymer Sodium alginate Pigment substitute Aluminum hydroxide [Table 2]: Orange pigment film coating used in [Figure 2B] Film coating composition Film-forming polymer Iron-based PVAP Water-soluble plasticizer PEG 3500 Auxiliary film-forming polymer Sodium alginate Pigment particles FD&C Yellow No. 6 Suppository Yellow S [Table 3]: Blue pigment film coating used in [Figure 2C] 2023.03 10 Compound dosage (percentage of total dry weight) 75.6 11.8 1.5 11.1 Compound dosage (percentage of total dry weight) 75.6 11.8 1.5 11.1 HK 30137243 A Instructions for Use: Film Coating Compound Components and Amounts (Percentage of Total Dry Weight) Film-forming polymer: Iron-based PVAP 75.6 Water-soluble plasticizer: PEG 3500 11.8 Film-forming auxiliary polymer: Sodium alginate 1.5 Pigment particles: FD&C Blue No. 2 (Oil Blue) 11.1 Addition of blush red silica microparticles [Table 4]: Blue pigment film coating containing silica microparticles used in [Figure 4] Film Coating Components and Amounts (Percentage of Total Dry Weight) Film-forming polymer: Iron-based PVAP 75.6 Water-soluble plasticizer: PEG 3500 11.8 Group 1: Silica microparticles Amorphous nanoporous silica microparticles 1 Silica microparticles Film-forming auxiliary polymer: Sodium alginate 1.5 Pigment particles: FD&C Blue No. 2 (Oil Blue) 11.1 After the film coating is sprayed and before the film dries, each oral pharmaceutical composition is pressed into a pattern in which a first group of silica microparticles is staggered and arranged adjacent to a second group of silica microparticles. Subsequently, the film-coated oral pharmaceutical composition is allowed to dry according to the specification 100002 2023.03 11 HK 30137243 A.
[0042] Those skilled in the art should further understand that variations and combinations of the features described above are not substitutes or alternatives, and can be combined to form more embodiments within the scope of this utility model.100002 2023.03 12 HK 30137243 A Claim 1. An oral pharmaceutical composition, characterized in that it comprises: (a) a formulation comprising: (i) a diaminophenazine (DAPTZ) compound as an active ingredient, said diaminophenazine compound being selected from methylene blue (MT+) compounds, colorless methylene blue (LMT) compounds, or combinations thereof; (ii) one or more other accompanying active ingredients, additives, excipients, diluents, binders, lubricants, disintegrants, fillers, stabilizers, surfactants, antioxidants, or combinations thereof; (b) a film coating covering said formulation, comprising: a film-forming polymer, a water-soluble plasticizer, a film-forming auxiliary polymer, and blue pigment particles; (c) carbon dioxide microparticles embedded within said film coating and / or attached to said film coating surface. 2. The oral pharmaceutical composition of claim 1, characterized in that the film-forming polymer comprises titanium-polyvinyl acetate phthalate (Titanium-PVAP). 3. The oral pharmaceutical composition of claim 1, characterized in that the water-soluble plasticizer comprises polyethylene glycol. 4. The oral pharmaceutical composition of claim 1, characterized in that the auxiliary film-forming polymer comprises sodium alginate. 5. The oral pharmaceutical composition of claim 1, characterized in that the blue pigment particles comprise a 1H-toluene-5-sulfonic acid, 2-(1,3-dihydro-3-oxo-5-sulfonyl-2H-1-toluene-2-yl)-2,3-dihydro-3-oxo-aluminum complex. 6. The oral pharmaceutical composition of claim 1 or 5, characterized in that the absorption wavelength range of the blue pigment particles is 600 nm to 610 nm. 7. The oral pharmaceutical composition of claim 1, characterized in that the silica microparticles comprise amorphous nanoporous silica microparticles, wherein each amorphous nanoporous silica microparticle contains two or more different pore sizes. 8. The oral pharmaceutical composition of claim 1, characterized in that the silica microparticles comprise two groups of amorphous nanoporous silica microparticles, wherein each microparticle in the first group of amorphous nanoporous silica microparticles contains at least two or more different pore sizes and has a first detectable spectral range; each microparticle in the second group of amorphous nanoporous silica microparticles contains at least two or more different pore sizes and has a second detectable spectral range, wherein the first detectable spectral range differs from the second detectable spectral range.100001 2023.03 HK 30137243 A Claim 9. The oral pharmaceutical composition according to claim 8, characterized in that, a first group of amorphous nanoporous silica particles and a second group of amorphous nanoporous silica particles are staggered and arranged in adjacent positions on the film coating to form a pattern. 10. The oral pharmaceutical composition according to claim 1, characterized in that, its shape includes a plurality of interior angles greater than 90°. 2 100001 2023.03 HK 30137243 A HK 30137243 A HK 30137243 A HK 30137243 A
